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Article Synopsis: 
Prescription drug monitoring programs (PDMP) may be effective tools to reduce drug diversion 
and improve clinical decision-making for pharmacists, but can only be effective if utilized. This 
cross-sectional study examined the relationship between outpatient pharmacists’ use of Indiana’s 
PDMP (INSPECT) and perceived barriers. Pharmacists were significantly more likely to use 
INSPECT if they reported no barriers. Pharmacists extremely concerned with prescription drug 
abuse were 18 times more likely to use INSPECT more consistently compared to those not at all 
concerned.  Innovative strategies to reduce administrative barriers to INSPECT must include 







BACKGROUND: Prescription drug monitoring programs (PDMPs) are proving to be valuable 2 
resources in fighting the prescription drug abuse epidemic through improved access to patient 3 
drug histories.  Ninety-four percent of Indiana pharmacists have heard of Indiana’s PDMP 4 
(INSPECT), only 71% of them reported using the program in 2012. 5 
OBJECTIVE: To identify barriers to PDMP use in outpatient pharmacies and determine the 6 
impact these barriers have on utilization.  7 
METHODS: A cross-sectional study examined pharmacists’ knowledge and use of INSPECT. 8 
Bivariate analyses on utilization and perceived barriers were conducted using cross-tabulations 9 
and X2. Multiple logistic regression examined the relationship between pharmacists’ level of 10 
concern with prescription drug abuse and reported utilization.   11 
RESULTS:  Pharmacists were significantly less likely to use INSPECT if they reported at least 12 
one barrier and 3 times more likely to use INSPECT if they reported no barrier.  Pharmacists 13 
were 10 times more likely to use INSPECT and 18 times more likely to use it more consistently 14 
if they were extremely concerned about prescription drug abuse in their community as compared 15 
to those not at all concerned.    16 
CONCLUSION: Strategies to improve utilization of PDMPs should look for innovative ways to 17 
limit barriers and build outpatient pharmacists’ awareness of prescription drug abuse and misuse 18 
within their community. 19 
  20 
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INTRODUCTION 21 
In the 1990s, health care quality improvement initiatives focused on raising awareness for 22 
the problem of inadequately treated pain.1 After the adoption of new standards for the 23 
management of pain, the United States saw an increase in prescribing of opioid analgesics. 24 
Between 1997 and 2007, the distribution of opioid drugs increased by over 7 times.2 Overdoses 25 
from prescription opioid pain relievers (OPR) quadrupled between 1999 and 2010.3 OPR 26 
overdoses remains a serious public health problem with 5.6 deaths per 100,000 individuals in 27 
2012. 3 A national approach to addressing prescription drug overdoses attempts to “balance the 28 
desire to minimize abuse with the need to ensure legitimate access to these medications”.4  One 29 
section of this plan calls for the establishment of prescription drug monitoring programs 30 
(PDMPs) in all 50 states.  A PDMP is a statewide electronic database that collects detailed data 31 
on controlled substance prescriptions (CSPs) in a state.5, 6  PDMPs have proven to be invaluable 32 
tools in fighting the prescription drug abuse epidemic by reducing drug diversion of controlled 33 
substances and improving clinical decision-making through increased access to detailed patient 34 
drug histories.7   35 
Pharmacists have an important role in the effort to address prescription drug abuse and 36 
are the “last line of defense”. A recent study suggested that more consistent use of PDMPs by 37 
pharmacists resulted in a higher number of refusals to dispense CSPs as a result of greater access 38 
to patient information.8 “Limited access to information affects [outpatient] pharmacists in 39 
fundamental ways, most specifically having incomplete prescription information which can leave 40 
the pharmacist unable to fill the prescription”.9 Pharmacists’ utilization of PDMPs may lead to a 41 
decrease in the morbidity and mortality associated with prescription drug abuse.10 Utilization of 42 
PDMPs in pharmacy practice may be beneficial to reducing the impact of prescription drug 43 
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abuse on the community, but a good portion of pharmacists do not utilize these programs.  An 44 
evaluation of the Indiana Scheduled Prescription Electronic Collection and Tracking Program 45 
(INSPECT), Indiana’s PDMP, showed that among the 94% of pharmacists who had heard of 46 
INSPECT only 72% of them reported actually using the program.11 PDMPs may prove to be 47 
effective tools to increasing access to patient information and supporting clinical decisions 48 
regarding the dispensation of CSPs, but they can only be effective if they are used. 49 
The primary objective of this study was to identify common barriers to INSPECT use 50 
reported by outpatient pharmacists and subsequently examine how these barriers influence 51 
PDMP utilization. The study also looked at a provider’s level of concern with Rx drug abuse in 52 
the community to assess how awareness of Rx abuse and misuse translates to INSPECT 53 
utilization.  54 
METHODS 55 
Study Design 56 
This cross-sectional study examined information on providers’ practice characteristics, 57 
behaviors, and key information about their knowledge and use of INSPECT.  The 2012 IPLA 58 
Knowledge and Use Survey was conducted by the Indiana University Purdue University – 59 
Indianapolis (IUPUI) Center for Health Policy (CHP) as part of an initiative to evaluate Indiana’s 60 
PDMP.  Detailed methodology for the evaluation is described in an previous report.11 The 61 
evaluation surveyed 10,606 pharmacists in the State of Indiana who held a valid license to 62 
dispense controlled substances in 2012.  With 1,582 pharmacists responding, the survey returned 63 
a 15% response rate. Basic demographics of the study sample were compared to Indiana’s 2012 64 
Pharmacist Workforce Data12 in a previous study8 to ensure the sample was representative of 65 
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Indiana’s total pharmacist population. The sample exhibited similar characteristics to Indiana’s 66 
2012 Pharmacist workforce in regards to age, years practicing, and gender.8  67 
Study Population 68 
The study population included 1,000 outpatient pharmacists who completed the 2012 69 
IPLA Knowledge and Use Survey.  Pharmacists were considered to be working in an outpatient 70 
setting if they reported their primary practice setting as a community health center, diagnostic 71 
testing facility, outpatient clinic, outpatient surgery center, pharmacy (outpatient), retail medicine 72 
clinic, or an urgent care facility. Otherwise, the pharmacist was excluded from the study. 73 
Study Outcomes 74 
The study consisted of 2 primary outcome measures.  The first outcome measure, Used 75 
INSPECT, is a binary variable (Yes=1, No=0) indicating whether or not the pharmacist reported 76 
using INSPECT within the last 12 months. The second outcome measure, “Often Check 77 
INSPECT, is a 3 level categorical variable (Never=1, Periodically=2, At Every Visit=3) that 78 
indicates the pharmacist’s reported frequency of INSPECT use.  79 
Data Analyses 80 
Statistical analyses were performed using SAS Statistical Software 9.4©. Descriptive 81 
statistics were performed to describe the study sample.  Cross-tabulations and X2 statistics were 82 
used to identify differences in INSPECT use by gender, age, training period, and reported 83 
barriers.  Relative risks were calculated to look at reported barriers as predictors of INSPECT 84 
use.  85 
Multiple logistic regression was used to study 2 outcome variables, Used INSPECT and 86 
Often Check INSPECT. Variables that were contextually relevant or statistically significant in 87 
the bivariate analyses were added to the initial multiple logistic regression models to control for 88 
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factors that may influence the relationship between the primary outcome measures and the 89 
dependent variable.  Degree type was not available in these data and so the variable training 90 
period was created to control for the time in which the provider was trained in relation to the 91 
adoption of the PharmD as the sole entry level degree for the pharmacy profession.8  Stepwise 92 
elimination was used to fit the model and to exclude any variables that had no statistical or 93 
conceptual significance in the multivariate model.13 The study outcome measures were assessed 94 
with determination of odds ratio (OR) estimates and 95% Wald confidence intervals (CIs).   95 
 RESULTS 96 
Barriers to INSPECT Utilization 97 
Basic demographic information describing the sample population is provided in Table 1. 98 
Although 97% of outpatient pharmacists had heard of INSPECT prior to receiving the survey, 99 
only 81% of them reported using it.  Furthermore, only 3% of outpatient pharmacists reported 100 
using INSPECT at every visit compared to periodically (88%) or never (9%) using INSPECT. 101 
All respondents who had heard of INSPECT were asked to report perceived barriers to using the 102 
PDMP.  The frequency of reported barriers to INSPECT and there association to INSPECT use 103 
(relative risk) is included in Table 2. If a pharmacists reported no barrier, they were 3 times more 104 
likely to also report using INSPECT; however, they were significantly less likely to use 105 
INSPECT if they reported at least one barrier (RR=.80).  Surprisingly, pharmacists who reported 106 
being afraid of legal ramifications were the least likely to report using INSPECT (RR=.44). 107 
The study also aimed to examine how barriers effect the frequency of INSPECT use. 108 
Figure 1 illustrates the variation in the frequency of INSPECT use based on respondents 109 
perceived barriers.  Not surprisingly, when no barriers were reported there was a larger 110 
percentage (14%) of pharmacists utilizing INSPECT at every visit as compared to when at least 111 
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one barrier was reported (7%).  No pharmacists who reported being afraid of legal ramifications 112 
utilized INSPECT at every visit.   113 
Pharmacists Level of Concern  114 
 Multiple logistic regressions examined the relationship between INSPECT use and the 115 
provider’s level of concern with prescription drug abuse in the community.  These results (Table 116 
3) demonstrated that outpatient pharmacists who reported being extremely concerned with 117 
prescription drug abuse in the community were approximately 10 times more likely to use 118 
INSPECT as compared to those who reported being not at all concerned (OR = 9.96, 95% CI, 119 
1.724 – 57.536).  Not only were those pharmacists extremely concerned with prescription drug 120 
abuse in the community more likely to report using INSPECT, but they were 18 times more 121 
likely to use INSPECT more frequently than those who were not at all concerned (OR = 17.89, 122 
95% CI, 1.457 – 219.69). 123 
DISCUSSION 124 
Pharmacists play a crucial role in the national efforts to reduce the abuse and misuse of 125 
CSPs.  Pharmacists have the responsibility to investigate the validity of CSPs if there is any 126 
reason to question the authenticity of the prescription.  However, many times outpatient 127 
pharmacists find themselves devoid of the proper clinical resources or information to resolve 128 
concerns that may arise while filling a CSP. PDMPs may provide key information to pharmacists 129 
allowing them to make informed clinical decisions reducing the risk of drug diversion.  This 130 
study illustrated that there are barriers to using INSPECT which results in outpatient pharmacists 131 
failing to utilize the program as frequently as may be desired. When pharmacists reported no 132 
barrier they were significantly more likely to use INSPECT.  Conversely, if there was at least 133 
one reported barrier the provider was significantly less likely to use INSPECT.  Interestingly, 134 
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10% of outpatient pharmacists reported that they were afraid of the perceived legal ramifications 135 
that may accompany use of the program.  Although this is not necessarily an administrative 136 
barrier, it may indicate that health professionals should look to raise awareness and provide 137 
comprehensive training for INSPECT users. These findings suggest that health professionals 138 
must look for innovative ways to ameliorate the impact key barriers including reimbursement, 139 
time, registration, and legal ramifications may have on utilization of INSPECT in order to fully 140 
leverage the potential of Indiana’s PDMP.  These results are also in line with conclusions from 141 
another study which examined PDMP utilization for primary care physicians.14 142 
These findings suggest that health professionals should look to remove barriers to 143 
INSPECT use and also to build awareness within the pharmacy community about prescription 144 
drug abuse in order to promote more consistent use of the PDMP.  Outpatient pharmacists were 145 
10 times more likely to report using INSPECT if they were extremely concerned with 146 
prescription drug abuse as compared to those who were not concerned at all.  Also, outpatient 147 
pharmacists were 18 times more likely to use INSPECT more often if they were extremely 148 
concerned as compared to those who were not concerned at all.  Therefore, it is possible that 149 
building awareness about prescription drug abuse within the pharmacy community may 150 
significantly increase the number of pharmacists not only using the PDMP, but using it more 151 
frequently.   152 
Study Limitations 153 
This study was conducted within one state, Indiana.  The generalizability of these 154 
findings to other states may be a limitation. Furthermore, the response rate for the survey was 155 
low and may be a limitation to the study.  A previous study compared Indiana’s 2012 pharmacist 156 
workforce to the survey sample and confirmed the survey sample comparable to Indiana’s 157 
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pharmacist workforce. Another limitation to this study was response bias as the outcome 158 
measures were self-reported.  It is likely that response bias may result in an overestimate of 159 
pharmacists use of INSPECT as well as reported frequency of use.  The survey was administered 160 
anonymously to limit response bias. In light of these limitations, the study findings should still 161 
be considered due to their important implications and consistency with previous literature.   162 
CONCLUSION 163 
This study concludes that strategies to improve outpatient pharmacists’ utilization of 164 
PDMPs should look for innovative ways to limit administrative barriers and also build outpatient 165 
pharmacists’ awareness of prescription drug abuse and misuse within their community.  166 
  167 
9 
Acknowledgements 168 
This research was supported, in part, by an evaluation contract to the second author from 169 
the Indiana Professional Licensing Agency (IPLA) made possible by a grant from the U.S. 170 
Department of Justice, Office of Justice Programs and the Harold Rogers Prescription Drug 171 
Monitoring Program (IPLA Contract No. 062166-00002B).   The authors would like to 172 
acknowledge the collaborative effort between the IPLA, the Indiana State Prescription Drug 173 
Abuse Prevention Task Force Education Committee, and the Indiana University Purdue 174 
University – Indianapolis, (IUPUI) Center for Health Policy (CHP) which led to the development 175 
of the IPLA Knowledge and Use Survey used in this study. The content is solely the 176 
responsibility of the authors and does not necessarily represent the official views of the Indiana 177 
Board of Pharmacy or the aforementioned collaborators.   178 
10 
REFERENCES 179 
1. Quality improvement guidelines for the treatment of acute pain and cancer pain. 180 
American Pain Society Quality of Care Committee. JAMA. 1995;274:1874-1880. 181 
2. Centers for Disease Control Prevention. CDC grand rounds: prescription drug overdoses - 182 
a U.S. epidemic. MMWR. Morbidity and mortality weekly report. 2012;61:10-13. 183 
3. Rudd RA, Paulozzi LJ, Bauer MJ, et al. Increases in Heroin Overdose Deaths—28 States, 184 
2010 to 2012. MMWR: Morbidity and mortality weekly report. 2014;63:849-854. 185 
4. Centers for Disease C, Prevention. CDC grand rounds: prescription drug overdoses - a 186 
U.S. epidemic. MMWR. Morbidity and mortality weekly report. 2012;61:10-13. 187 
5. NAMSDL. The role of a prescription drug monitoring program in reducing prescription 188 
drug diversion, misuse, and abuse: National Alliance for Model State Drug Laws; 2014. 189 
6. Blumenschein K, Fink J, Freeman PR, et al. Review of Prescription Drug Monitoring 190 
Programs in the United States: Institute for Pharmaceutical Outcomes and Policy; 191 
2010:1-28. 192 
7. PDMP Center of Excellence. Briefing on PDMP Effectiveness. Brandeis University: 193 
Bureau of Justice Assistance; 2014. 194 
8. Norwood CW, Wright ER. Integration of Prescription Drug Monitoring Programs 195 
(PDMP) in Pharmacy Practice: Improving Clinical Decision-Making and Supporting a 196 
Pharmacist’s Professional Judgment. Research in Social and Administrative Pharmacy. 197 
2015. 198 
9. Maxwell L, Odukoya OK, Stone JA, Chui MA. Using a conflict conceptual framework to 199 
describe challenges to coordinated patient care from the physicians' and pharmacists' 200 
perspective. Research in social & administrative pharmacy : RSAP. 2014;10:824-836. 201 
11 
10. Fleming MLPDa, Barner JCPDb, Brown CMPDb, Shepherd MDPDb, Strassels SPDb, 202 
Novak SMDPDb. Using the theory of planned behavior to examine pharmacists' intention 203 
to utilize a prescription drug monitoring program database. Research In Social & 204 
Administrative Pharmacy. 2014;10:285-296. 205 
11. Kooreman H, Carnes N, Wright E. Key Findings and Recommendations from the 2013 206 
IPLA INSPECT Knowledge and Use Survey. Center for Health Policy: Indiana 207 
University; 2014. 208 
12. Maxey HL. Indiana Pharmacist 2012 Licensure Survey Data. In: Indiana University 209 
Health Workforce Studies, ed2015. 210 
13. Menard S. Applied Logistic Regression Analysis. Thousand Oaks, CA: Sage; 2002. 211 
14. Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most primary care physicians 212 
are aware of prescription drug monitoring programs, but many find the data difficult to 213 




TABLES & FIGURES 217 
Table 1 
Sample Demographics 
 N (%) 
Age (years) Mean ± SD, 46.4 ± 13.6 
Years Practicing Mean ± SD, 20.5 ± 14.0 
Gender  
     Female 521 (54) 
     Male 445 (46) 
Race/Ethnicity (n=1000)  
     White/non-Hispanic 898 (93) 
     Asian American/ Pacific Islander 28 (3) 
     Black/non-Hispanic 17 (2) 
     American Indian/ Alaska Native 3 (0) 
     Hispanic/Latino 11 (1) 
Training Period  
     Cohort 1 272 (28) 
     Cohort 2 302 (31) 
     Cohort 3 393 (41) 
Barriers to INSPECT  
Insufficient Time 532 (58) 
Not Registered 129 (14) 
Lack of Reimbursement 89 (10) 
Other Barriers 96 (10) 
Afraid of Legal Ramifications 26 (3) 







Sample Demographics and Bivariate Analysis 
 Total Respondents Used Inspect    
Outpatient Pharmacists  Yes No X2 P  
Age Category    11.67 .0086  
     <35 265 (29) 224 (25) 41 (5)    
     36-45 198 (22) 170 (19) 28 (3)    
     46-55 177 (19) 142 (16) 35 (4)    
     56+ 272 (30) 204 (22) 68 (8)    
Gender    .0232 .8790  
     Female 521 (54) 400 (44) 96 (10)    
     Male 445 (46) 342 (37) 80 (9)    
Training Period    10.211 .0061  
     Cohort 1 272 (28) 223 (24) 42 (5)    
     Cohort 2 302 (31) 244 (27) 44 (5)    
     Cohort 3 393 (41) 272 (30) 89 (9)    
Barriers to INSPECT      
Relative Risk  
(95% Confidence Interval)
No Barriers  532 (58) 268 (29) 20 (2) 38.86 <.0001 3.112* (2.0381, 4.751) 
At Least One Barrier 638 (68) 492 (52) 146 (16) 18.23 <.0001 .7960* (.7290, .8692) 
Not Registered 129 (14) 38 (4) 91 (10) 262.29 <.0001 .0970* (.069, .1363) 
Afraid of Legal Ramifications 89 (10) 17 (2) 9 (1) 4.35 0.037 .4386* (.1989, .9673) 
Lack of Reimbursement 96 (10) 71 (7) 18 (2) .1226 .7262 .9160 (.5611, 1.495) 
Insufficient Time 26 (3) 444 (48) 88 (10) 4.3914 .0361 1.172* (1.001, 1.3721) 
Other Barriers 288 (31) 75 (8) 21 (2) .6435 .4225 .8293 (.5263, 1.3068) 
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Multivariate Logistic Regression 
 Used INSPECT  Often Check INSPECT  
  95% CI    95% CI   
Variable OR Lower Upper P  OR Lower Upper P  
Male 0.88 .592 1.30 .509  1.095 .648 1.85 .734  
Age (in years) 1.03 .999 1.06 .060  .963 .925 1.00 .072  
Training Period           
     Cohort 1 1.11 0.465 2.667 .230  .603 .166 2.20 .443  
     Cohort 2 .672 .351 1.29 .809  .852 .335 2.17 .736  
     Cohort 3 ref ref ref ref  ref ref ref ref  
Rx Abuse in Community           
Extremely Concerned ref ref ref ref  ref ref ref ref  
Moderately Concerned .743 .495 1.12 .153  .733 .425 1.26 .264  
Slightly Concerned 1.17 .624 2.18 .629  .402 .146 1.10 .077  
Not concerned at all 9.96 1.72 57.54 .010  17.89 1.457 219.69 .024  
  
 226 
